The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.

Shares of at least four other developers were up by mid-single digits to low-double digits at certain points on Tuesday.

A review of recent research suggests that the testing methods may have led to overly optimistic expectations. A competitive drug has been approved and appears to be making excellent commercial headway ...

Compass Pathways' Phase 3 COMP-360 data met primary endpoints but disappointed versus analyst expectations, triggering a 50% stock drop and highlighting sector skepticism. Key hurdles for Compass ...